Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP7 | P09237 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346270 | 0.85 | ALDH1A1 (0.43) | TSHRGHSR | |
| SCHEMBL7058802 | 0.85 | TSHR (0.41) | TSHRC3AR1MMP1MMP3MMP7 | |
| Hydrochloric Acid SCHEMBL7053243 | 0.84 | NAMPT (0.46) | NAMPTGPR183MMP1MMP3MMP7 | |
| Hydrochloric Acid SCHEMBL7053241 | 0.84 | NAMPT (0.46) | NAMPTGPR183MMP1MMP3MMP7 | |
| SCHEMBL7657242 | 0.84 | NAMPT (0.38) | NAMPTHCRTR1C3AR1FNTAFNTB | |
| SCHEMBL7056073 | 0.82 | SMN1; SMN2 (0.36) | HCRTR1TSHRMMP1MMP3MMP7 | |
| SCHEMBL7057786 | 0.82 | MCHR1 (0.36) | HCRTR1MMP1MMP3MMP9MMP13 | |
| SCHEMBL7059076 | 0.82 | SMN1; SMN2 (0.36) | HCRTR1MMP1MMP3MMP7MMP9 | |
| SCHEMBL7054549 | 0.81 | HCRTR1 (0.37) | HCRTR1MMP1MMP3MMP7MMP9 | |
| SCHEMBL7058722 | 0.81 | HCRTR1 (0.41) | HCRTR1TSHRMMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | NAMPT 1436/4885HCRTR1 772/4885TSHR 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.